Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter

Michael Lim(Stanford University), Antonio Omuro(Johns Hopkins University), Ingo K. Mellinghoff(Memorial Sloan Kettering Cancer Center), Kevin Petrecca(McGill University Health Centre), Joachim M. Baehring(Yale University), Solmaz Sahebjam(Johns Hopkins University), Masashi Kinoshita(Kanazawa University), Ruta Slepetis(Bristol-Myers Squibb (United States)), Filip De Vos(University Medical Center Utrecht), Antje Wick(Heidelberg University), Gaetano Finocchiaro(Istituti di Ricovero e Cura a Carattere Scientifico), Deepti Warad(Bristol-Myers Squibb (United States)), Raju R. Raval(The Ohio State University Wexner Medical Center), David A. Reardon(Dana-Farber Cancer Institute), Jérôme Honnorat(Université Claude Bernard Lyon 1), Joachim P. Steinbach(Goethe University Frankfurt), Mustimbo Roberts(Bristol-Myers Squibb (United States)), George Ansstas(Washington University in St. Louis), Jennie Taylor(University of California, San Francisco), David Leung(Prince of Wales Hospital), Ashley Sumrall(Levine Cancer Institute), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Michelle H. Lee(Syneos Health (United States)), Michael Weller(University Hospital of Zurich)

Neuro-Oncology

April 28, 2022

Cited by 508

|Science Translational Medicine|2014|5.1k

|The Lancet Neurology|2016|4.4k

|Nature Genetics|2019|4.4k

|JCO Precision Oncology|2017|2.7k

|Annals of Neurology|2007|2.5k

Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter